# US 8,278,307 B2 · Monocyclic Heteroaryl compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,307 B2
- Document ID: US8278307B2
- Status: Granted
- Kind: B2
- Application number: 12/227,130
- Filed: 2007-05-08
- Published: 2009-06-11
- Granted: 2012-10-02
- Earliest claimed: 2006-05-08
- Assignees: ARIAD Pharmaceuticals, Inc.
- Inventors: William C. Shakespeare; Wei-Sheng Huang; David C. Dalgarno; Xiaotian Zhu; R. Mathew Thomas; Yihan Wang; Jiwei Qi; Rajeswari Sundaramoorthi; Dong Zou; Chester A. Metcalf, III; Tomi K. Sawyer; Jan Antoinette C. Romero
- Web page: https://patentgrep.com/patent/US8278307B2

## CPC

- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 277/40: Unsubstituted amino or imino radicals
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

## Claims

### Claim 1

A compound of the Formula:
or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
Ring T represents
Ring A represents a 5- or 6-membered aryl or heteroaryl ring;
Ring B represents a 5- or 6-membered aryl or heteroaryl ring;
L1 is NR1C(O) or C(O)NR1;
each Ra and Rt is independently selected from halo, —CN, —NO2, —R4, —OR2, —NR2R3, —C(O)YR2, —OC(O)YR2, —NR2C(O)YR2, —SC(O)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)YR2, —YP(═O)(YR4)(YR4), —Si(R4)3, —NR2SO2R2, —S(O)rR2, —SO2NR2R3 and —NR2SO2NR2R3, wherein Y is independently a bond, —O—, —S— or —NR3—;
each R1, R2 and R3 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocycle and heteroaryl, and in addition, NR2R3 may be a 5- or 6-membered saturated, partially saturated or unsaturated ring, which is optionally substituted and contains 0-2 additional heteroatoms selected from N, O and S(O)r;
each R4 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;
Rb is selected from halo, —CN, —NO2, —R4, —OR2, —NR2R3, —C(O)YR2, —OC(O)YR2, —NR2C(O)YR2, —SC(O)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)YR2, —YP(═O)(YR4)(YR4), —Si(R4)3, —NR2SO2R2, —S(O)rR2, —SO2NR2R3, and —NR2SO2NR2R3, Ring C, and —L2-Ring D, wherein Y is independently a bond, —O—, —S— or —NR3—;
in which:
(i) Ring C is a 5- or 6-membered heteroaryl or heterocyclic ring comprising carbon atoms and 1-3 heteroatoms independently selected from O, N and S(O)r and which is optionally substituted with 1 to 5 substituents, Rc;
(ii) L2 is (CH2)z, O(CH2)x, NR3(CH2)x, S(CH2)x, and (CH2)xNR3C(O)(CH2)x, oriented in either direction; and,
(iii) Ring D is a 5- or 6-membered heterocyclic or heteroaryl ring comprising carbon atoms and 1-3 heteroatoms independently selected from O, N and S(O)r and which is optionally substituted with 1 to 5 Rd substituents;
each Rc and Rd is independently halo, ═O, ═S, —CN, —NO2, —R4, —OR2, —NR2R3, —Si(R4)3, —C(O)YR2, —OC(O)YR2, —NR2C(O)YR2, —SC(O)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)YR2, —YP(═O)(YR4)2, —NR2SO2R2, —S(O)rR2, —SO2NR2R3 or —NR2SO2NR2R3;
each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl moieties is optionally substituted;
m is 0, 1, 2, 3 or 4;
n is 0, 1, 2 or 3;
p is 1, 2, 3, 4 or 5;
r is 0, 1 or 2;
x is 0, 1, 2 or 3;
z is 1, 2, 3 or 4;
each optional substituent for an unsaturated carbon atom of an aryl or heteroaryl moiety and for a carbon atom of an alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl or non-aromatic heterocyclic group is selected from F, Cl, Br, I, —CN, —R4, —OR2, —S(O)rR2, —SO2NR2R3, —NR2R3, —(CO)YR2, —O(CO)YR2, —NR2(CO)YR2, —S(CO)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)Y′R2, —COCOR2, —COMCOR2, —YP(═O)(YR4)(YR4), —Si(R2)3, —NO2, —NR2SO2R2 and —NR2SO2NR2R3, where M is a 1-6 carbon alkyl group;
each optional substituent for an alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl or non-aromatic heterocyclic group alternatively is selected from ═O, ═S, ═NH, ═NNR2R3, ═NNHC(O)R2, ═NNHCO2R2, and ═NNHSO2R2; and
each optional substituent on a nitrogen is selected from R4, —NR2R3, —C(═O)R2, —C(═O)OR2, —C(═O)SR2, —C(═O)NR2R3, —C(═NR2)NR2R3, —C(═NR2)OR2, —C(═NR2)R3, —COCOR2, —COMCOR2, —CN, —SO2R3, S(O)R3, —P(═O)(YR2)(YR2), —NR2SO2R3 and —NR2SO2NR2R3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein at least one of Rb is
or a tautomer or a pharmaceutically acceptable salt thereof, wherein:
v is 0, 1, 2, 3, 4 or 5.

### Claim 3 (depends on 2)

The compound according to claim 2, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Ring C is a heteroaryl ring bearing a single C1-C6 alkyl substituent.

### Claim 4 (depends on 3)

The compound of claim 3 or a tautomer or a pharmaceutically acceptable salt thereof, in which Ring C is selected from the following:

### Claim 5 (depends on 2)

The compound according to claim 2, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Ring C is one of the following:

### Claim 6 (depends on 2)

The compound of claim 2, or a tautomer or a pharmaceutically acceptable salt thereof, having the formula:

### Claim 7 (depends on 6)

The compound of claim 6, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Rt is —CH3 or —C(O)NH2, v is 1, n is 0 or 1, m is 1, t is 1, Ra is —CH3, Rb is CF3 and Rc is —CH3.

### Claim 8 (depends on 1)

The compound according to claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Rings A and B are aryl.

### Claim 9 (depends on 1)

The compound of claim 1, or a tautomer or a pharmaceutically acceptable salt thereof, wherein at least one of Rb is
wherein:
Ring D represents a 5- or 6-membered heterocyclic or heteroaryl ring, comprising carbon atoms and 1-3 heteroatoms independently selected from N, O, S(O)r;
L2 is (CH2)z, O(CH2)x, NR3(CH2)x, S(CH2)x or (CH2)xNR3C(O)(CH2)x and the linkage unit can be used in either direction;
Rd, at each occurrence, is selected from the group consisting of halo, ═O, ═S, —CN, —NO2, —R4, —OR2, —NR2R3, —C(O)YR2, —OC(O)YR2, —NR2C(O)YR2, —SC(O)YR2, —NR2C(═S)YR2, —OC(═S)YR2, —C(═S)YR2, —YC(═NR3)YR2, —YP(═O)(YR4)(YR4), —Si(R4)3, —NR2SO2R2, —S(O)rR2, —SO2NR2R3 and —NR2SO2NR2R3, wherein Y is independently a bond, —O—, —S— or —NR3—;
R2 and R3 are independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;
alternatively, NR2R3 moiety may be a 5- or 6-membered saturated, partially saturated or unsaturated ring, which can be optionally substituted and which contains 0-2 additional heteroatoms selected from N, O and S(O)r;
each occurrence of R4 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic and heteroaryl;
each of the foregoing alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and heterocycle moieties is optionally substituted;
w is 0, 1, 2, 3, 4 or 5;
x is 0, 1, 2 or 3;
z is 1, 2, 3 or 4; and
t is 0, 1, 2, 3, or 4.

### Claim 10 (depends on 9)

The compound according to claim 9, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Rings A and B are aryl.

### Claim 11 (depends on 9)

The compound of claim 9, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Ring D is a substituted or unsubstituted piperazine ring and L2 is CH2.

### Claim 12 (depends on 11)

The compound of claim 11, or a tautomer or a pharmaceutically acceptable salt thereof, having the formula:

### Claim 13 (depends on 12)

The compound of claim 12, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Rt is independently selected from —CH3 and —C(O)NH2, n is 0 or 1, m is 1, t is 1, Ra is methyl, Rb is CF3, and Rd is selected from methyl and CH2CH2OH.

### Claim 14 (depends on 9)

The compound of claim 9, or a tautomer or a pharmaceutically acceptable salt thereof, wherein Ring D is a substituted or unsubstituted heteroaryl ring.

### Claim 15 (depends on 9)

The compound of claim 9 or a tautomer or a pharmaceutically acceptable salt thereof, in which Ring B-L2-Ring D is selected from the following:

### Claim 16 (depends on 1)

The compound of claim 1 or a tautomer or a pharmaceutically acceptable salt thereof, in which Ring T is selected from:

### Claim 17 (depends on 1)

The compound of claim 1 or a tautomer or a pharmaceutically acceptable salt thereof, in which Ring T is selected from the following:

### Claim 18 (depends on 1)

The compound of claim 1 or a tautomer or a pharmaceutically acceptable salt thereof, in which Ring A is selected from the following:

### Claim 19 (depends on 1)

The compound of claim 1 or a tautomer or a pharmaceutically acceptable salt thereof, in which Ring B is selected from the following:

### Claim 20

A compound selected from the following:
or a pharmaceutically acceptable salt thereof.

### Claim 21

A compound selected from the following:
1-Methyl-5-(2-methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide,
1-Methyl-5-(2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide,
5-[5-(3-Imidazol-1-yl-5-trifluoromethylphenylcarbamoyl)-2-methyl-phenylethynyl]-1-methyl-1H-imidazole-2-carboxylic acid amide,
N-{3-chloro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}-4-methyl-3-[(1-methyl-1H-imidazol-5-yl)ethynyl]benzamide,
1-methyl-5-({2-methyl-5-[({4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbonyl)amino]phenyl}ethynyl)-1H-imidazole-2-carboxamide, and
5-[(5-{[4-{[(3R)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)phenyl]carbamoyl}-2-methylphenyl)ethynyl]-1-methyl-1H-imidazole-2-carboxamide,
or a pharmaceutically acceptable salt thereof.

### Claim 22

The compound 1-Methyl-5-(2-methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof.

### Claim 23

The compound 1-Methyl-5-(2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenylcarbamoyl]-phenylethynyl)-1H-imidazole-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof.

### Claim 24

The compound 5-[5-(3-Imidazol-1-yl-5-trifluoromethylphenylcarbamoyl)-2-methyl-phenylethynyl]-1-methyl-1H-imidazole-2-carboxylic acid amide or a pharmaceutically acceptable salt thereof.

### Claim 25

The compound N-{3-chloro-4-[(4-methylpiperazin-1-yl)methyl]phenyl}-4-methyl-3-[(1-methyl-1H-imidazol-5-yl)ethynyl]benzamide or a pharmaceutically acceptable salt thereof.

### Claim 26

The compound 1-methyl-5-({2-methyl-5-[({4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}carbonyl)amino]phenyl}ethynyl)-1H-imidazole-2-carboxamide or a pharmaceutically acceptable salt thereof.

### Claim 27

The compound 5-[(5-{[4-{[(3R)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)phenyl]carbamoyl}-2-methylphenyl)ethynyl]-1-methyl-1H-imidazole-2-carboxamide or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A composition comprising a compound of any of claim 1, 2, 8, 3, 5, 6, 7, 9, 10, 11, 14, 12, 13, 16 or 17, 18, 19, 4, 15, 20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
